Compare what actually differs.
BPC-157 vs TB-500
A source-backed comparison of two unapproved recovery-market peptides.
Tesamorelin vs Sermorelin
Current approval and evidence context for two GHRH analogs.
Tesamorelin vs Ipamorelin
An approved GHRH analog compared with an unapproved ghrelin-receptor agonist.
MOTS-c vs SS-31
Two mitochondrial peptides with sharply different clinical status.
CJC-1295 vs Ipamorelin
Early endocrine research compared without treating biomarker changes as outcomes.
Retatrutide vs Tirzepatide
An investigational triple agonist compared with an approved dual agonist.
Retatrutide vs Semaglutide
Investigational triple-receptor research compared with a mature GLP-1 evidence base.
Tirzepatide vs Semaglutide
Two approved metabolic medicines compared without flattening product labels or trial populations.
Ipamorelin vs Sermorelin
Two unapproved growth-hormone-axis peptides with different mechanisms and evidence histories.
CJC-1295 vs Sermorelin
A long-acting GHRH analog compared with a shorter historical GHRH fragment.
CJC-1295 vs Tesamorelin
An unapproved endocrine research peptide compared with an indication-specific approved medicine.
BPC-157 vs Thymosin Beta-4
Two tissue-repair research stories compared without translating preclinical signals into recovery claims.
TB-500 vs Thymosin Beta-4
A marketed fragment name compared with the full-length endogenous peptide it is often confused with.
BPC-157 vs GHK-Cu
Preclinical recovery claims compared with limited route-specific topical human research.
BPC-157 vs KPV
Two unapproved peptides discussed for inflammation and gastrointestinal research.
Thymosin Alpha-1 vs Thymosin Beta-4
Two distinct thymosin peptides with different biology, research programs, and sport status.
Thymosin Alpha-1 vs LL-37
An immune-modulating therapeutic candidate compared with an endogenous antimicrobial peptide.
KPV vs LL-37
Two innate-immune research peptides with different mechanisms and similarly limited therapeutic evidence.
Epitalon vs MOTS-c
Two longevity-market peptides compared by verifiable human evidence rather than anti-aging narratives.
Epitalon vs SS-31
A longevity research peptide compared with a molecule that has one rare-disease accelerated approval.
Semax vs Selank
Two neuroactive research peptides compared without treating regional studies as settled evidence.
Semax vs DSIP
Limited neurologic research compared with a very small historical sleep-peptide record.
Selank vs DSIP
A small anxiety research program compared with historical sleep-peptide studies.
PT-141 vs Melanotan II
An FDA-reviewed bremelanotide product compared with an unapproved melanocortin analog.
AOD-9604 vs Tesamorelin
A growth-hormone fragment with an unsuccessful obesity program compared with a narrow approved GHRH analog.
Tesamorelin vs Semaglutide
A narrow HIV-lipodystrophy medicine compared with product-specific metabolic indications.
Tesamorelin vs Tirzepatide
Indication-specific HIV-lipodystrophy evidence compared with dual-incretin metabolic evidence.
AOD-9604 vs Semaglutide
An unapproved growth-hormone fragment compared with an extensively studied GLP-1 medicine.
AOD-9604 vs Tirzepatide
An unapproved growth-hormone fragment compared with an approved dual-incretin medicine.
TB-500 vs GHK-Cu
Two recovery-market peptides compared by entity identity, route, and human evidence.
GHK-Cu vs Thymosin Beta-4
Copper-peptide research compared with full-length thymosin beta-4 research without crossing routes or molecules.